NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Second Affiliated Hospital of Nanchang University
Conditions: Non-Small Cell Lung Cancer
Interventions: Spatially Fractionated Radiotherapy (SFRT), Tislelizumab, Carboplatin, Pemetrexed, Tislelizumab, paclitaxel, Carboplatin
Countries: China
The aim of this clinical trial is to understand whether spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment is effective in treating initially unresectable stage Ⅲ non-small cell lung cancer (NSCLC). It will also explore the safety of this treatment modality. The main questions it aims to answer are: Will spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment increase the surgical resection rate of patients with initially unresectable stage Ⅲ non-small cell lung cancer? What adverse reactions will patients experience when receiving spatial fractionated radiotherapy (SFRT) in combination with tislelizumab and platinum-based doublet chemotherapy given concurrently as induction treatment?
Sex: ALL
Age: 18 Years to 85 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * The patient has histologically or cytologically confirmed stage III non-small cell lung cancer (NSCLC) that is deemed unresectable after discussion in the multidisciplinary team (MDT), which is classified as T3-4N1-2M0 according to the 8th edition of the American Joint Committee on Cancer (AJCC). Exclusion Criteria: * Has participated in another clinical study using research products within the past 3 weeks.
- Nanchang, Jiangxi, China